Drug management of early rheumatoid arthritis - 2008

Best Practice and Research: Clinical Rheumatology

Volumn 23, Issue 1, 2009, Pages 93-102

  Sokka, Tuulikki ^a,b   Mäkinen, Heidi ^a,c  

^a JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^b Finland MedCare Ltd   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

DMARDs; early rheumatoid arthritis; methotrexate

Indexed keywords

ABATACEPT; ADALIMUMAB; AURANOFIN; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FOLIC ACID; GLUCOCORTICOID; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; PENICILLAMINE; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE;

BONE RADIOGRAPHY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE CONTROL; DISEASE DURATION; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY INTERVENTION; FUNCTIONAL ASSESSMENT; HUMAN; LOW DRUG DOSE; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; THERAPY DELAY; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; WORK DISABILITY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; EARLY DIAGNOSIS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 60449090955     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2008.08.003     Document Type: Review

References (99)

1. Kelley W.N., Harris Jr. E.D., Ruddy S., and Sledge C.B. Textbook of rheumatology. 2nd edn. (1985), W.B.Saunders, Philadelphia
2. Short C.L., and Bauer W. The course of rheumatoid arthritis in patients receiving simple medical and orthopedic measures. N Engl J Med 238 (1948) 142-148
3. Pincus T., Callahan L.F., Sale W.G., et al. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 27 (1984) 864-872
4. Scott D.L., Grindulis K.A., Struthers G.R., et al. Progression of radiological changes in rheumatoid arthritis. Ann Rheum Dis 43 (1984) 8-17
5. Yelin E., Meenan R., Nevitt M., and Epstein W. Work disability in rheumatoid arthritis: effects of disease, social, and work factors. Ann Intern Med 93 (1980) 551-556
6. Luukkainen R., Kajander A., and Isomäki H. Treatment of rheumatoid arthritis (letter). Br Med J 2 (1978) 1501
7. Wilske K.R., and Healey L.A. Remodeling the pyramid - a concept whose time has come. J Rheumatol 16 (1989) 565-567
8. Fries J.F. Reevaluating the therapeutic approach to rheumatoid arthritis: the 'sawtooth' strategy. J Rheumatol 17 Suppl. 22 (1990) 12-15
9. Emery P., and Salmon M. Early rheumatoid arthritis: time to aim for remission?. Ann Rheum Dis 54 (1995) 944-947
10. Sokka T., and Pincus T. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum 48 2 (2003) 313-318
11. Gogus F., Yazici Y., and Yazici H. Inclusion criteria as widely used for rheumatoid arthritis clinical trials: patient eligibility in a Turkish cohort. Clin Exp Rheumatol 23 5 (2005) 681-684
12. Pincus T., and Sokka T. Quantitative measures for assessing rheumatoid arthritis in clinical trials and clinical care. Best Pract Res Clin Rheumatol 17 (2003) 753-781
13. Bergstrom U., Book C., Lindroth Y., et al. Lower disease activity and disability in Swedish patients with rheumatoid arthritis in 1995 compared with 1978. Scand J Rheumatol 28 (1999) 160-165
14. Pincus T., Sokka T., and Kautiainen H. Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. Arthritis Rheum 52 (2005) 1009-1019
15. Sokka T., Möttönen T., and Hannonen P. Disease-modifying anti-rheumatic drug use according to the 'sawtooth' treatment strategy improves the functional outcome in rheumatoid arthritis: results of a long-term follow-up study with review of the literature. Rheumatology 39 (2000) 34-42
16. Krishnan E., and Fries J.F. Reduction in long-term functional disability in rheumatoid arthritis from 1977 to 1998: a longitudinal study of 3035 patients. Am J Med 115 (2003) 371-376
17. Heiberg T., Finset A., Uhlig T., and Kvien T.K. Seven year changes in health status and priorities for improvement of health in patients with rheumatoid arthritis. Ann Rheum Dis 64 (2005) 191-195
18. Sokka T.M., Kaarela K., Möttönen T.T., and Hannonen P.J. Conventional monotherapy compared to a 'sawtooth' treatment strategy in the radiographic procession of rheumatoid arthritis over the first eight years. Clin Exp Rheumatol 17 (1999) 527-532
19. Sokka T., Kautiainen H., Häkkinen K., and Hannonen P. Radiographic progression is getting milder in patients with early rheumatoid arthritis. Results of 3 cohorts over 5 years. J Rheumatol 31 (2004) 1073-1082
20. Krause D., Schleusser B., Herborn G., and Rau R. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 43 (2000) 14-21
21. Choi H.K., Hernán M.A., Seeger J.D., et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359 (2002) 1173-1177
22. Jacobsson L.T.H., Turesson C., Nilsson J.A., et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 66 5 (2007) 670-675
23. Sokka T., Kautiainen H., and Hannonen P. Stable occurrence of knee and hip total joint replacement in Central Finland between 1986 and 2003: an indication of improved long-term outcomes of rheumatoid arthritis. Ann Rheum Dis 66 3 (2007) 341-344
24. da Silva E., Doran M.F., Crowson C.S., et al. Declining use of orthopedic surgery in patients with rheumatoid arthritis? Results of a long-term, population-based assessment. Arthritis Rheum 49 2 (2003) 216-220
25. Ward M.M. Decreases in rates of hospitalizations for manifestations of severe rheumatoid arthritis, 1983-2001. Arthritis Rheum 50 (2004) 1122-1131
26. Weiss R.J., Stark A., Wick M.C., et al. Orthopaedic surgery of the lower limbs in 49,802 rheumatoid arthritis patients: results from the Swedish National Inpatient Registry during 1987 to 2001. Ann Rheum Dis 65 3 (2006) 335-341
27. Fevang B., Lie S., Havelin L., et al. Reduction in orthopedic surgery among patients with chronic inflammatory joint disease in Norway 1994-2004. Arthritis Care Res 57 3 (2007) 529-532
28. Kobelt G., Eberhardt K., and Geborek P. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 63 1 (2004) 4-10
29. Puolakka K., Kautiainen H., Mottonen T., et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 52 1 (2005) 36-41
30. Sokka T., Kautiainen H., Toloza S., et al. QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis 66 (2007) 1491-1496
31. Symmons D.P.M., Hazes J.M.W., and Silman A.J. Cases of early inflammatory polyarthritis should not be classified as having rheumatoid arthritis. J Rheumatol 30 (2003) 902-904
32. Allbutt T., and Rolleston H. A system of medicine (1907), Macmillan, London
33. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 (1988) 315-324
34. Harrison B.J., Symmons D.P.M., Barrett E.M., and Silman A.J. The performance of the 1987 ARA classification criteria for rheumatoid arthritis in a population based cohort of patients with early inflammatory polyarthritis. J Rheumatol 25 (1998) 2324-2330
35. Saraux A., Berthelot J.M., Chalès G., et al. Ability of the American College of Rheumatology 1987 criteria to predict rheumatoid arthritis in patients with early arthritis and classification of these patients two years later. Arthritis Rheum 44 11 (2001) 2485-2491
36. Helliwell P.S. The semeiology of arthritis: discriminating between patients on the basis of their symptoms. Ann Rheum Dis 54 (1995) 924-926
37. Kaarela K. Prognostic factors and diagnostic criteria in early rheumatoid arthritis. Scand J Rheumatol Supplement 57 (1985) 1-54
38. Möttönen T.T. Prediction of erosiveness and rate of development of new erosions in early rheumatoid arthritis. Ann Rheum Dis 47 (1988) 648-653
39. Hannonen P., Möttönen T., Hakola M., and Oka M. Sulfasalazine in early rheumatoid arthritis. Arthritis Rheum 36 (1993) 1501-1509
40. Machold K.P., Stamm T.A., Eberl G.J., et al. Very recent onset arthritis-clinical, laboratory, and radiological findings during the first year of disease. J Rheumatol 29 11 (2002) 2278-2287
41. Buckland-Wright J.C., Clarke G.S., Chikanza I.C., and Grahame R. Quantitative microfocal radiography defects changes in erosion area in patients with early rheumatoid arthritis treated with myocrisine. J Rheumatol 20 (1993) 243-247
42. Egsmose C., Lund B., Borg G., et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol 22 (1995) 2208-2213
43. van der Heide A., Jacobs J.W., Bijlsma J.W., et al. The effectiveness of early treatment with 'second-line' antirheumatic drugs: a randomized controlled trial. Ann Intern Med 124 (1996) 699-707
44. Choy E.H., Scott D.L., Kingsley G.H., et al. Treating rheumatoid arthritis early with disease modifying drugs reduces joint damage: a randomised double blind trial of sulphasalazine vs diclofenac sodium. Clin Exp Rheumatol 20 3 (2002) 351-358
45. Tsakonas E., Fitzgerald A.A., Fitzcharles M.A., et al. Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the Hydroxychloroquine in Early Rheumatoid Arthritis (HERA) Study. J Rheumatol 27 3 (2000) 623-629
46. Anderson J.J., Wells G., Verhoeven A.C., and Felson D.T. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 43 1 (2000) 22-29
47. van Dongen H., van Aken J., Lard L.R., et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 56 (2007) 1424-1432
48. Möttönen T., Hannonen P., Leirisalo-Repo M., et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 353 (1999) 1568-1573
49. Pinals R.S., Masi A.T., Larsen R.A., et al. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 24 (1981) 1308-1315
50. Puolakka K., Kautiainen H., Mottonen T., et al. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis. A five-year randomized followup trial. Arthritis Rheum 50 (2004) 55-62
51. Puolakka K., Kautiainen H., Mottonen T., et al. Predictors of productivity loss in early rheumatoid arthritis: a 5 year follow up study. Ann Rheum Dis 64 (2005) 130-133
52. Soubrier M., Puechal X., Sibilia J., et al. Evaluation of two strategies (initial methotrexate monotherapy versus its combination with adalimumab) in management of early active rheumatoid arthritis during the first year of evolution: Data from the GUEPARD trial. EULAR (2008) [abstract]
53. Leirisalo-Repo M., Kautiainen H., Laasonen L., et al. A randomized, double-blind, placebo-controlled study on addition of infliximab to the FIN-RACo DMARD combination therapy for initial six months in patients with early active rheumatoid arthritis. The NEO-RACo study. EULAR (2008) [abstract]
54. Luukkainen R., Kajander A., and Isomäki H. Effect of gold on progression of erosions in rheumatoid arthritis: better results with early treatment. Scand J Rheumatol 6 (1977) 189-192
55. Lard L.R., Visser H., Speyer I., et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 111 (2001) 446-451
56. Wiles N.J., Lunt M., Barrett E.M., et al. Reduced disability at five years with early treatment of inflammatory polyarthritis: results from a large observational cohort, using propensity models to adjust for disease severity. Arthritis Rheum 44 (2001) 1033-1042
57. Nell V.P., Machold K.P., Eberl G., et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 43 (2004) 906-914
58. Verstappen S.M.M., Jacobs J., Bijlsma J.W.J., et al. Five-year followup of rheumatoid arthritis patients after early treatment with disease-modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year. Arthritis Rheum 48 (2003) 1797-1807
59. Sokka T. Early rheumatoid arthritis in Finland. Clin Exp Rheumatol 21 (2003) S133-S137
60. Jantti J.K., Kaarela K., Belt E.A., and Kautiainen H.J. Incidence of severe outcome in rheumatoid arthritis during 20 years. J Rheumatol 29 4 (2002) 688-692
61. Kaarela K., and Kautiainen H. Continuous progression of radiological destruction in seropositive rheumatoid arthritis. J Rheumatol 24 (1997) 1285-1287
62. Häkkinen A., Sokka T., Kotaniemi A., and Hannonen P. A randomized two-year study of the effects of dynamic strength training on muscle strength, disease activity, functional capacity, and bone mineral density in early rheumatoid arthritis. Arthritis Rheum 44 (2001) 515-522
63. Möttönen T., Paimela L., Ahonen J., et al. Outcome in patients with early rheumatoid arthritis treated according to the 'sawtooth' strategy. Arthritis Rheum 39 (1996) 996-1005
64. Möttönen T., Paimela L., Leirisalo-Repo M., et al. Only high disease activity and positive rheumatoid factor indicate poor prognosis in patients with early rheumatoid arthritis treated with 'sawtooth' strategy. Ann Rheum Dis 57 (1998) 533-539
65. Sokka T., Möttönen T., and Hannonen P. Mortality in early 'sawtooth' treated rheumatoid arthritis patients during the first 8-14 years. Scand J Rheumatol 28 (1999) 282-287
66. Sokka T., Kautiainen H., Möttönen T., and Hannonen P. Work disability in rheumatoid arthritis 10 years after the diagnosis. J Rheumatol 26 (1999) 1681-1685
67. Sokka T., and Hannonen P. Utility of disease modifying antirheumatic drugs in 'sawtooth' strategy. A prospective study of early rheumatoid arthritis patients up to 15 years. Ann Rheum Dis 58 (1999) 618-622
68. Pincus T., Ferraccioli G., Sokka T., et al. Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Rheumatology 41 (2002) 1346-1356
69. Walji S., and Bykerk V.P. Rheumatoid arthritis: is the disease becoming milder or is treatment improving?. J Rheumatol 31 (2004) 1023-1025
70. Hakkinen A., Sokka T., Kautiainen H., et al. Sustained maintenance of exercise induced muscle strength gains and normal bone mineral density in patients with early rheumatoid arthritis: a 5 year follow up. Ann Rheum Dis 63 (2004) 910-916
71. Hakkinen A., Sokka T., Lietsalmi A.M., et al. Effects of dynamic strength training on physical function, Valpar 9 work sample test, and working capacity in patients with recent-onset rheumatoid arthritis 3. Arthritis Rheum 49 1 (2003) 71-77
72. Scott D.L., Symmons D.P., Coulton B.L., and Popert A.J. Long-term outcome of treating rheumatoid arthritis: Results after 20 years. Lancet 16 (1987) 1108-1111
73. Combe B., Landewe R., Lukas C., et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 66 1 (2007) 34-45
74. Pincus T., Yazici Y., Sokka T., et al. Methotrexate as the 'anchor drug' for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 21 (2003) S179-S185
75. Wolfe F., and Michaud K. The clinical and research significance of the erythrocyte sedimentation rate. J Rheumatol 21 (1994) 1227-1237
76. Pincus T., and Sokka T. Prevalence of normal erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) on presentation of patients with rheumatoid arthritis (RA) at two rheumatology settings, one in the US and the other in Finland: Is a patient questionnaire a better quantitative measure of clinical severity?. Arthritis Rheum 52 9 (2005) S127 [abstract]
77. Mikkelsen W.M., and Dodge H. A four year follow-up of suspected rheumatoid arthritis: the Tecumseh, Michigan, community health study. Arthritis Rheum 12 (1969) 87-91
78. O'Sullivan J.B., and Cathcart E.S. The prevalence of rheumatoid arthritis: follow-up evaluation of the effect of criteria on rates in Sudbury, Massachusetts. Ann Intern Med 76 (1972) 573-577
79. Pincus T., and Callahan L.F. The 'side effects' of rheumatoid arthritis: joint destruction, disability and early mortality. Br J Rheumatol 32 Suppl.1 (1993) 28-37
80. Möttönen T., Hannonen P., Korpela M., et al. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 46 4 (2002) 894-898
81. Grigor C., Capell H., Stirling A., et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364 (2004) 263-269
82. Fransen J., Moens H.B., Speyer I., and van Riel P.L.C.M. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised contolled trial. Ann Rheum Dis 64 (2005) 1294-1298
83. Verstappen S.M., Jacobs J.W., van der Veen M.J., et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 66 11 (2007) 1443-1449
84. Goekoop-Ruiterman Y.P.M., de Vries-Bouwstra J.K., Allaart C.F., et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52 (2005) 3381-3390
85. Paulus H.E. Defining remission in rheumatoid arthritis: what is it? Does it matter?. J Rheumatol 31 1 (2004) 1-4
86. Sokka T., Hetland M., Makinen H., et al. Remission and Rheumatoid Arthritis. Data from 24 Countries in the QUEST-RA Study. Arthritis Rheum 58 9 (2008) 2642-2651
87. Kremer J.M. Toward a better understanding of methotrexate. Arthritis Rheum 50 5 (2004) 1370-1382
88. Pincus T., Marcum S.B., and Callahan L.F. Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second-line drugs and prednisone. J Rheumatol 19 (1992) 1885-1894
89. Wolfe F., Hawley D.J., and Cathey M.A. Termination of slow acting anti-rheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 17 (1990) 994-1002
90. Maetzel A., Wong A., Strand P., et al. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology 39 (2000) 975-981
91. Chan E.S.L., and Cronstein B.N. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 4 (2002) 266-273
92. Donahue K.E., Gartlehner G., Jonas D.E., et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 148 2 (2008) 124-134
93. Pincus T., Yazici Y., and Sokka T. Are excellent systematic reviews of clinical trials useful for patient care?. Nat Clin Pract Rheumatol 4 6 (2008) 294-295
94. Bathon J.M., Martin R.W., Fleischmann R.M., et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343 (2000) 1586-1593
95. Breedveld F.C., Weisman M.H., Kavanaugh A.F., et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54 (2006) 26-37
96. Miyasaka N., and Koike R. Treatment guidelines for the use of biologics in rheumatoid arthritis; present and future. Nippon Rinsho 65 7 (2007) 1169-1178
97. Hench P.S., Kendall E.C., Slocumb C.H., and Polley H.F. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of the pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin 24 (1949) 181
98. Pincus T., Sokka T., and Stein C.M. Are long-term very low doses of prednisone for patients with rheumatoid arthritis as helpful as high doses are harmful?. Ann Intern Med 136 1 (2002) 76-78
99. Boers M., Verhoeven A.C., Markusse H.M., et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350 (1997) 309-318